Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease

Zinc homeostasis could play a role in compensated advanced chronic liver disease, and its supplementation has been linked to improvement in liver function, a decrease of hepatic complications, and reduction in HCC incidence. Compensated advanced chronic liver disease encompasses a heterogeneous grou...

Descripción completa

Detalles Bibliográficos
Autores: Bañares, Juan|||0000-0002-1966-1947, Aceituno, Laia|||0000-0001-5414-2408, Ruiz-Ortega, Lourdes|||0000-0003-3636-3367, Pons Delgado, Mònica|||0000-0002-0985-3320, Abraldes, Juan G.|||0000-0003-3421-937X, Genescà Ferrer, Joan|||0000-0002-0831-8422
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:322328
Acceso en línea:https://ddd.uab.cat/record/322328
https://dx.doi.org/urn:doi:10.1097/HC9.0000000000000524
Access Level:acceso abierto
Palabra clave:Cirrhosis
First decompensation
Hepatocellular carcinoma
Portal hypertension
Zinc
Descripción
Sumario:Zinc homeostasis could play a role in compensated advanced chronic liver disease, and its supplementation has been linked to improvement in liver function, a decrease of hepatic complications, and reduction in HCC incidence. Compensated advanced chronic liver disease encompasses a heterogeneous group of patients with variable risks of clinically significant portal hypertension and clinical events. The ANTICIPATE model is a validated model for stratifying these risks. Our aim is to demonstrate that zinc administration can reduce the rate and risk of presenting clinical events (first decompensation, HCC, death, and liver transplantation). This study protocol describes an ongoing phase III, national, multicenter, randomized, double-blind clinical trial that will enroll 300 patients to receive either the trial treatment (zinc acexamate) or placebo. An inclusion period of 42 months is planned, with a minimum follow-up of 2 years. Our principal hypothesis is that zinc could modify the natural history of patients with compensated advanced chronic liver disease, with an overall improvement in prognosis.